SWIR Camera Lens for Pharmaceutical Inspection: Tablet, Capsule, Powder and Packaging Material Differentiation

Pharmaceutical inspection is fundamentally different from conventional appearance-based machine vision because two products can look almost identical while differing significantly in formulation, active ingredient distribution, excipient ratio, coating condition, capsule content or packaging material. A white tablet manufactured correctly and another tablet with poor blend uniformity may have the same visible colour. Two capsules can use identical shell colours while containing different formulations. Fine pharmaceutical powders can appear uniform to the eye even when segregation has occurred. Packaging films that look transparent or visually similar can also have different material compositions. These are not primarily colour-inspection problems; they are material differentiation and chemical-uniformity problems, which is why SWIR and near-infrared spectral imaging have become important tools for non-destructive pharmaceutical quality inspection.

A SWIR camera lens for pharmaceutical inspection provides the optical pathway needed to image wavelength-dependent differences across the short-wave infrared region. Pharmaceutical ingredients contain molecular bonds whose absorption behaviour varies with wavelength, so active pharmaceutical ingredients, excipients, coatings, capsule shells, powders and selected packaging materials can produce different spectral responses even when conventional cameras cannot distinguish them visually. Near-infrared chemical imaging research has demonstrated spatial mapping of active ingredients and excipients in tablets, assessment of blend homogeneity, coating distribution and non-destructive pharmaceutical identity verification.

The dedicated Kyptec Automation® SWIR Camera Lens collection currently provides 8.5 mm, 12.5 mm, 25 mm, 35 mm and 50 mm focal-length options. The live portfolio is specified for 900–1700 nm wavelength operation, 2 MP resolution, 2/3-inch sensor format, F1.4 aperture and C-Mount, and pharmaceutical quality control is explicitly identified among its intended industrial applications. This combination gives pharmaceutical-machine OEMs a focused optical platform for building inspection stations ranging from wider tablet and capsule transport systems to narrower powder-analysis or high-detail dosage-form inspection cells.

Why SWIR Adds Information That Visible Pharmaceutical Inspection Cannot Provide

Visible inspection is excellent for detecting broken tablets, missing capsules, incorrect colour, obvious coating defects, dimensional variation and surface contamination. Its limitation appears when the relevant quality attribute does not generate a visible difference.

A pharmaceutical formulation contains active pharmaceutical ingredient, fillers, binders, disintegrants, lubricants, coatings and other components. These substances interact differently with near-infrared and SWIR wavelengths because their chemical structures generate different spectral absorption patterns. When this spectral information is recorded spatially, the imaging system can create a material map rather than only a photograph.

This is the key distinction between ordinary pharmaceutical machine vision and SWIR-based material inspection.

A conventional camera can answer, “Is there a tablet here, and what does it look like?” A properly developed spectral imaging system can address questions closer to, “Does this region of the tablet behave like the expected formulation, and is that material distributed consistently across the inspected area?”

Research on pharmaceutical tablets has shown that near-infrared chemical imaging can distinguish and map both active ingredients and excipients, providing spatial information that conventional bulk spectroscopy does not capture.

Tablet Inspection: Identity Is Only the First Level

One straightforward pharmaceutical application is tablet identity verification. Different formulations can produce different spectral signatures even when tablets share similar visual appearance.

For an industrial inspection system, however, product identity should not be the final ambition. A stronger system can also examine whether the spatial spectral pattern matches the validated product.

For example, two tablets can contain the correct total quantity of active material while distributing that material differently. A bulk analytical result may not reveal that spatial heterogeneity, whereas chemical imaging can identify localized regions associated with different components.

Published pharmaceutical imaging work has demonstrated that NIR spectral imaging can differentiate tablets ranging from well blended to deliberately unblended formulations and can quantify changes in blend homogeneity from spatial intensity distributions.

For an OEM, this makes tablet blend uniformity inspection a distinct engineering problem from ordinary tablet presence or colour inspection.

Why API Distribution Matters in a Tablet Image

Consider a tablet in which active pharmaceutical ingredient should be distributed relatively uniformly through the formulation. If processing conditions create segregation or agglomeration, certain regions can become richer or poorer in API.

A visible camera may show a perfectly normal tablet.

A spectral image, however, can potentially identify localized differences because every image pixel contains wavelength-dependent information. After calibration or multivariate analysis, pixels associated with API and major excipients can be mapped spatially.

Research has demonstrated quantitative and spatial assessment of API and excipient distribution in tablets using near-infrared chemical imaging, including formulations containing multiple components.

For production equipment, the optical system must therefore provide enough spatial sampling to resolve the size of the heterogeneity that matters. A 2 mm formulation agglomerate and a whole-tablet identity check do not require the same field of view.

Blend Uniformity Begins Before Compression

Powder blending is a critical manufacturing step because the final dosage form depends on consistent distribution of formulation components. Segregation can occur during mixing, transfer, hopper discharge or subsequent processing, meaning a powder stream that appears visually homogeneous may contain significant compositional variation.

This makes SWIR powder inspection potentially valuable at several stages of pharmaceutical manufacturing.

In a controlled imaging configuration, the system can compare spectral behaviour across regions of a powder sample or moving powder bed. If a component-rich region produces a different spectral signature from the intended blend, imaging can reveal spatial non-uniformity rather than only reporting an overall average.

The difficulty is that powders introduce strong scattering and surface-topography effects. Particle size, packing density, surface height and illumination angle can change measured intensity even without a chemical change. A production system must therefore separate chemical variation from physical sampling variation through controlled sample presentation, representative calibration and appropriate spectral preprocessing.

Sampling Area Is Critical for Powder Blend Inspection

An imaging system does not measure an entire industrial blender simultaneously. It measures the material that appears inside the optical field at a particular moment.

This creates an important process-engineering question: does the imaged sample represent the complete powder process?

Research on continuous pharmaceutical manufacturing highlights effective sampling size, sampling location and robustness to process variation as major issues in near-infrared blend-uniformity monitoring.

For an OEM, lens selection therefore cannot be separated from process location.

A very narrow FOV may provide excellent spatial resolution but inspect too little powder to represent the process. An excessively wide FOV may increase sample area but reduce the spatial detail needed to reveal segregation.

The correct optical field is the one that represents the process adequately while retaining the spatial resolution required by the target non-uniformity.

Capsule Inspection Requires Separation of Shell and Content Information

Capsules create a different problem because the camera may receive spectral information from both the shell and the formulation inside it.

The shell is not optically invisible. Its material, colour, thickness and manufacturing variation can all influence the recorded spectrum. Research on non-invasive capsule inspection has demonstrated that spectral measurements can contain information from the packaging or blister, capsule shell and capsule contents simultaneously.

This has two consequences for a production system.

If the objective is to verify the complete capsule product, shell variation may itself be relevant quality information.

If the objective is specifically to classify the formulation inside the capsule, the model should be designed so ordinary shell variation does not dominate the decision.

This distinction should be established before the optical system is commissioned.

Closed-Capsule Inspection Can Be Technically Valuable

One of the strongest practical advantages of spectral pharmaceutical inspection is the possibility of obtaining useful material information without opening or destroying every dosage form.

Studies of closed hard-shell capsules have shown that near-infrared methods can identify different APIs and formulations non-destructively, although quantitative measurement becomes more difficult at very low concentrations.

That distinction matters commercially.

Identification asks whether the capsule matches an approved spectral class.

Quantification asks how much of a particular component is present.

The second problem is substantially harder and requires stronger calibration, controlled variability and validated reference measurements.

An OEM should therefore avoid promising quantitative API measurement simply because qualitative capsule differentiation performs well.

Tablet Coating Can Be Inspected as a Material Distribution Problem

Tablet coating affects product appearance, release behaviour, protection and handling. Uneven coating can therefore become an important process-quality issue.

Near-infrared chemical imaging has demonstrated the ability to map coating distribution and estimate coating thickness while simultaneously evaluating tablet components. Research also shows that increasing coating thickness can reduce the predictive performance of models aimed at the underlying tablet core, which is an important practical limitation.

For an inspection-machine OEM, coating therefore creates two different requirements.

If coating itself is the target, the system should be optimized for coating contrast and uniformity.

If the objective is to inspect the formulation beneath the coating, the coating becomes part of the optical path and must be included explicitly in calibration.

A model developed on uncoated tablets should not automatically be transferred to coated production tablets.

Spatial Resolution Should Be Defined by the Smallest Pharmaceutical Non-Uniformity

The phrase “2 MP pharmaceutical inspection” is not sufficiently precise to determine whether an optical system can detect a real formulation problem.

Suppose a camera provides 1600 horizontal pixels and images a 160 mm transport width. Nominal object sampling is approximately:

160 mm ÷ 1600 pixels = 0.10 mm/pixel.

A 1 mm material anomaly could therefore occupy about ten pixels before optical blur, curvature and processing are considered.

If the same camera is required to cover 400 mm, nominal sampling becomes 0.25 mm/pixel and the same anomaly spans only about four pixels.

This is why field of view should be calculated from the smallest material region or defect that changes the pharmaceutical decision, not merely from conveyor width.

Kyptec Automation® KL-1410 for Wider Tablet and Capsule Transport Systems

For systems where multiple tablets or capsules must be inspected simultaneously from limited camera height, the Kyptec Automation® KL-1410 12.5 MM SWIR Camera Lens provides a relatively wide optical geometry while remaining inside the 900–1700 nm SWIR range. Its verified live specifications include 12.5 mm focal length, F1.4, 2 MP, 2/3-inch format and C-Mount.

This geometry can be useful to evaluate for tablet identity inspection, capsule differentiation and production stations where several dosage forms cross the inspection field at once.

The OEM should still calculate the pixel representation of the smallest coating or formulation region of interest. A wide field that reliably identifies the whole tablet may not provide enough spatial detail to characterize small localized non-uniformity.

Kyptec Automation® KL-1412 for Controlled Dosage-Form Inspection

The Kyptec Automation® KL-1412 25 MM SWIR Camera Lens provides an intermediate focal-length geometry that is particularly useful when the inspection system needs to devote more of the sensor to one tablet, capsule or controlled region.

Its current specifications include 25 mm focal length, 900–1700 nm spectral operation, F1.4 aperture, 2 MP resolution, 2/3-inch sensor format and C-Mount.

For an OEM, this geometry can be evaluated where the requirement moves beyond basic product identity toward more detailed spatial analysis of coating, component distribution or localized formulation differences.

The advantage is not that 25 mm is inherently “more accurate.” It becomes useful when the machine can trade some inspection width for better object representation.

Kyptec Automation® KL-1414 for Tighter Pharmaceutical Material Analysis

The Kyptec Automation® KL-1414 35 MM SWIR Camera Lens provides a narrower-field option within the current portfolio. Its published specifications include 35 mm focal length, 900–1700 nm, F1.4, 2 MP, 2/3-inch format and C-Mount, and the product page explicitly lists pharmaceutical inspection among its intended applications.

This geometry is especially relevant to controlled laboratory-to-production cells, localized tablet inspection, powder-analysis areas or material-verification stations where maximum conveyor width is not the dominant requirement.

Greater object representation can support more stable region-of-interest extraction, which becomes important when spectral analysis must isolate a specific area from surrounding background.

Packaging Materials Are Part of the Pharmaceutical Spectral Measurement

Pharmaceutical packaging should not be treated as optically neutral.

Transparent blister material, polymer films and capsule packaging can produce their own wavelength-dependent absorption. NIR research has demonstrated identification and quantitative characterization of pharmaceutical plastic packaging films, including measurement of packaging-sheet properties.

For an inspection machine, this creates two separate application opportunities.

The first is packaging material differentiation itself: confirming that the packaging film or polymer belongs to the approved material class.

The second is inspection through packaging where the SWIR system attempts to identify or characterize the dosage form through a transmitting package.

These should not be confused.

A material that works well for direct tablet inspection may behave differently when a blister film is inserted into the optical path.

Through-Blister Inspection Is Possible Only When the Package Preserves Useful Spectral Information

Non-invasive pharmaceutical inspection through blister packaging has been demonstrated using near-infrared methods. Studies have shown that tablets can be identified through blister-pack plastic, and multispectral imaging has also been used to obtain composition-related information from blister-packed tablets.

However, this should not be interpreted as meaning every blister package is SWIR-transparent.

The polymer material, thickness, coatings, printing, curvature and package geometry all influence transmission and reflection. Some portions of the packaging spectrum can also overlap with the pharmaceutical spectrum.

An OEM should therefore qualify the exact production blister structure, not an arbitrary transparent sheet.

The strongest validation uses final production packaging rather than bare tablets followed by an assumption that packaging will not matter.

Packaging Differentiation Can Support Incoming Material Verification

Another useful pharmaceutical application is comparing packaging materials themselves.

Two polymer sheets may look virtually identical but have different formulations, coatings or thicknesses. Near-infrared studies have demonstrated rapid qualitative identification of pharmaceutical packaging films and quantitative analysis of film thickness.

For an automated quality-control station, imaging can extend this concept spatially. A sheet, blister web or selected packaging region can be inspected for material consistency across an area rather than at only one point.

This application should be calibrated around approved packaging lots and expected production variation so the system distinguishes real material substitutions from harmless manufacturing variation.

Spectral Similarity Between API and Excipients Determines Classification Difficulty

Not every formulation component is easily separated.

Some pharmaceutical ingredients can have strongly different spectral signatures, while others overlap substantially. Published tablet chemical-imaging work has demonstrated that highly similar excipient spectra can make calibration more difficult even when the imaging hardware is unchanged.

This has an important implication for buyers: better optics cannot manufacture spectral separation that the materials do not possess.

Before designing a production inspection station, representative pure components and finished formulations should be characterized spectrally. The development team should determine whether the intended 900–1700 nm band provides enough separation for the required decision.

If two components are spectrally very similar, classification may need multiple wavelengths, stronger chemometric modelling or a different inspection objective.

Single-Wavelength Thresholding Is Usually Too Simplistic for Pharmaceutical Material Differentiation

A bright or dark pixel at one wavelength rarely proves pharmaceutical identity.

Tablet composition, surface roughness, compression, coating, illumination and sample angle can all change absolute intensity.

A stronger classifier examines the relationship among several spectral bands. Hyperspectral pharmaceutical research routinely uses multivariate approaches because formulation information is distributed across wavelengths rather than concentrated in one universal absorption feature.

For an OEM developing a production system, hyperspectral measurements can first be used to identify which wavelengths contribute most strongly to separation. The final machine can then be engineered around the information actually required by the validated classifier.

F1.4 Becomes Valuable When Exposure Time Is Limited

Tablets or capsules moving through an inspection line create an exposure-time constraint.

If products travel at 1 m/s and the camera uses a 500 µs exposure, the dosage form moves approximately 0.5 mm during image capture. For whole-tablet identity this may sometimes be acceptable; for small coating or material-distribution regions it can noticeably reduce spatial definition.

The F1.4 maximum aperture available across the Kyptec Automation® SWIR Camera Lens family provides useful optical throughput for short-exposure imaging.

The aperture should still be qualified against depth of field and edge performance. Maximum optical brightness is not automatically the best production setting.

Curved Tablets and Capsules Require Illumination Control

Tablets and capsules are not flat calibration targets. Curved surfaces produce changing reflection angles, and shiny coatings or shells can generate local highlights.

A spectral classifier can mistakenly interpret these brightness differences as material variation if illumination geometry is poorly controlled.

A pharmaceutical inspection station should therefore test the same validated tablet at multiple rotations and lateral positions. If its spectral class changes simply because orientation changes, the problem should be corrected optically or through normalization before the acceptance model is frozen.

This is especially important when a machine must inspect randomly oriented capsules.

Powder Inspection Requires Height and Packing-Density Control

Powders introduce another nuisance variable: the apparent spectrum can change as the powder bed becomes denser, rougher or more uneven.

A deeper powder bed can present a different scattering path from a thin layer. Local hills and valleys also change illumination angle.

For a controlled powder-quality station, the sample-presentation mechanism should therefore be treated as part of the optical system.

The strongest machine is not one that uses an increasingly complicated model to compensate for uncontrolled presentation. It is one that first makes the optical measurement repeatable.

Quantitative Claims Require Independent Reference Methods

There is an important difference between identifying a formulation and stating the amount of active ingredient present.

Hyperspectral imaging studies have demonstrated quantitative API prediction and spatial concentration mapping, including in-line pharmaceutical dosage-form applications.

But any production claim such as “API concentration is X%” requires a validated calibration built against an accepted independent analytical reference. The model must also remain robust across manufacturing lots, environmental variation and expected process conditions.

OEMs should therefore define whether the machine's goal is identity verification, pass/fail classification, uniformity mapping or quantitative concentration prediction before purchasing and integrating the optics.

Pharmaceutical Models Should Be Tested on New Batches, Not Only Training Samples

A classifier can perform extremely well on the batches used to create it and fail when raw-material properties or process conditions shift.

Independent validation should therefore include new production lots, expected formulation variability, coating variation, legitimate supplier variation and the actual packaging structure.

This becomes particularly important when a spectral system will be replicated across several lines or facilities.

The objective is not merely to achieve a high calibration score. The objective is to preserve classification performance when the process changes within its approved manufacturing range.

Reject Logic Should Include an Unknown or Out-of-Model Condition

A pharmaceutical inspection machine should not always force every tablet or capsule into one approved formulation class.

An unfamiliar product, severe defect, packaging mix-up or unusual material can produce spectral data outside every validated class.

Allowing a low-confidence or out-of-model state is therefore valuable. Products whose spectral behaviour falls outside the validated population can be diverted for secondary verification rather than assigned automatically to the closest known class.

This approach is particularly useful for identity inspection because it reduces the risk that an unexpected material is falsely accepted simply because the algorithm is required to choose something.

Why Kyptec Automation® Is a Strong SWIR Optical Platform for Pharmaceutical OEMs

The Kyptec Automation® SWIR Camera Lens collection gives pharmaceutical-equipment manufacturers five practical focal lengths—8.5 mm, 12.5 mm, 25 mm, 35 mm and 50 mm—within one focused SWIR platform. The live range maintains 900–1700 nm wavelength coverage, 2 MP resolution class, 2/3-inch format, F1.4 aperture and C-Mount across the product family.

That consistency is useful because pharmaceutical inspection can require several geometries. Wider lenses can support multiple tablets or capsules across a transport system. Intermediate focal lengths can focus more sensor area on individual dosage forms. Longer focal lengths can support controlled material-analysis cells or packaging-quality stations where tighter framing is more important than maximum field width.

Kyptec Automation® is therefore a strong specialized optical platform to evaluate for OEMs that want to build multiple pharmaceutical SWIR inspection architectures around one coherent lens family rather than select unrelated optics for each machine.

Frequently Asked Questions About SWIR Camera Lenses for Pharmaceutical Inspection

1. Can a SWIR inspection system distinguish tablets that have the same colour and shape?

Yes, when their formulations produce sufficiently different spectral responses. Visible similarity does not imply identical SWIR behaviour because active ingredients, excipients and coatings absorb and reflect infrared wavelengths differently. Pharmaceutical chemical-imaging studies have demonstrated differentiation and spatial mapping of formulation components that cannot be identified from tablet appearance alone.

2. Can SWIR imaging detect poor blend uniformity inside a finished tablet?

It can reveal surface or spatial heterogeneity associated with component distribution, and pharmaceutical studies have demonstrated clear differentiation between tablets produced from well-blended and poorly blended powders. The measurable result depends on component spectral contrast, sampling depth and the physical scale of the segregation. A production model should therefore be validated with deliberately varied blend-quality samples.

3. Can SWIR tell where the active pharmaceutical ingredient is located in a tablet?

Near-infrared chemical imaging can generate spatial maps associated with API and excipient distributions when their spectral responses can be separated. Published studies have successfully mapped pharmaceutical components across tablet surfaces. The result is model-dependent and should not be interpreted as direct chemical microscopy without appropriate calibration and validation.

4. Can SWIR identify different pharmaceutical powders before tablet compression?

Potentially yes. Powder components can produce distinct spectral responses, allowing blend composition and uniformity to be monitored. However, powder packing density, particle size and surface geometry influence the measurement, so controlled sampling and process-representative calibration are critical.

5. Can SWIR detect powder segregation during continuous pharmaceutical manufacturing?

Near-infrared techniques are widely studied for blend-uniformity monitoring in continuous manufacturing. The main challenges include effective sampling volume, sampling location and robustness against process variability. An imaging implementation must therefore inspect a representative portion of the powder stream rather than only produce a chemically detailed image of an unrepresentative region.

6. Can SWIR inspect the contents of a closed capsule?

In some capsule systems, near-infrared measurements can obtain useful formulation information through the shell. Published studies have demonstrated non-destructive identification of APIs in closed capsules. Capsule material and thickness still influence the spectrum, so the production model must include realistic shell variation.

7. Can capsule shell variation cause false pharmaceutical classification?

Yes. The shell itself contributes spectral information, and research has shown that shell properties can influence non-invasive pharmaceutical measurements. If only capsule contents matter, the model should be designed and validated to remain robust to acceptable shell variation. If shell quality is also part of the product specification, those differences may instead become useful inspection information.

8. Can SWIR imaging detect tablet coating non-uniformity?

Yes, where coating and underlying formulation provide sufficient spectral contrast. Near-infrared chemical imaging has been used to map coating distribution and estimate coating thickness. The coating can also attenuate information from the tablet core, so coating thickness must be represented during calibration.

9. Can a pharmaceutical product be inspected through blister packaging?

Potentially, when the blister material transmits enough useful near-infrared or SWIR information. Research has demonstrated non-invasive identification of tablets through blister packaging. However, polymer type, thickness and coatings influence the measurement, so the actual final package must be validated rather than assuming that all transparent blister materials are optically equivalent.

10. Can SWIR differentiate pharmaceutical packaging materials?

Yes, selected polymer packaging materials can produce distinct near-infrared spectra. Studies have demonstrated qualitative identification of pharmaceutical packaging films and quantitative measurement of film properties such as thickness. This creates potential for incoming-material verification and packaging consistency inspection when the approved packaging library has been validated adequately.

11. Which focal length is suitable for inspecting several tablets at once?

A shorter focal length is generally the first candidate when the system must cover several dosage forms from limited camera height. The Kyptec Automation® KL-1410 12.5 MM SWIR Camera Lens provides relatively broad coverage within the current range. Final selection should be based on transport width, sensor dimensions, working distance and the smallest material feature that must remain detectable.

12. When is a 25 mm SWIR lens better for pharmaceutical inspection?

The Kyptec Automation® KL-1412 25 MM SWIR Camera Lens becomes attractive when a smaller inspection field is acceptable and the machine benefits from assigning more pixels to individual tablets, capsules or powder regions. It can therefore suit detailed dosage-form inspection better than a wide-field system when transport geometry allows it.

13. Does higher spatial resolution automatically improve API identification?

No. Material identification requires spectral separation as well as spatial information. Increasing the number of pixels cannot compensate if the API and excipient have almost identical spectral behaviour within the selected wavelength region. The correct system balances spectral discrimination, object sampling and signal-to-noise performance.

14. Can SWIR directly measure API concentration without calibration?

Quantitative concentration measurement generally requires a validated analytical model and representative reference data. Hyperspectral research has demonstrated successful API concentration prediction, but those results depend on calibrated multivariate models and independent validation. Identity classification is usually a less demanding problem than precise concentration measurement.

15. Why does the same tablet sometimes produce different SWIR intensity after rotation?

Curved tablet surfaces and coatings change the reflection geometry as the product rotates. Illumination angle can therefore alter absolute intensity even without any formulation change. Production models should include multiple orientations and use stable illumination or spectral normalization so orientation does not become a false material signal.

16. Can one pharmaceutical SWIR system inspect tablets, capsules and powders?

The same 900–1700 nm optical platform can potentially support several pharmaceutical applications, but each product type requires separate optical qualification and classification models. A powder bed, capsule shell and coated tablet produce very different scattering and sampling conditions. Reusing hardware is possible; reusing one universal calibration without validation is not.

17. How should an OEM validate a pharmaceutical spectral-inspection machine?

Validation should include approved product, known formulation deviations, coating variation, different production lots, multiple orientations, expected transport speeds and the final packaging structure where relevant. Quantitative claims should be checked against an independent reference method, while identity and classification models should be tested using production samples that were not used to create the model.

18. What specifications should be provided when selecting a SWIR camera lens for pharmaceutical inspection?

Provide the camera sensor dimensions, inspection FOV, working distance, smallest relevant tablet or formulation feature, product speed, product height, intended 900–1700 nm spectral bands, dosage form, packaging condition and whether the objective is identity, blend uniformity, coating inspection, material differentiation or quantitative analysis. These details allow focal length to be selected around the true pharmaceutical inspection requirement.

19. Why is Kyptec Automation® a strong option for pharmaceutical SWIR inspection systems?

Kyptec Automation® provides a dedicated SWIR Camera Lens portfolio spanning 8.5 mm, 12.5 mm, 25 mm, 35 mm and 50 mm focal lengths while maintaining a common 900–1700 nm, 2 MP, 2/3-inch, F1.4 and C-Mount architecture. Pharmaceutical quality control is explicitly included among the published applications of the current range. This gives OEMs a practical way to build wider product-verification stations, intermediate dosage-form inspection systems and tighter material-analysis cells without leaving the dedicated Kyptec Automation® SWIR Camera Lens platform.

Conclusion

The strongest reason to use a SWIR camera lens for pharmaceutical inspection is that pharmaceutical quality is often determined by material composition rather than visible appearance. Tablets, capsules, powders, coatings and packaging materials can contain important differences that a conventional camera cannot reliably distinguish when colour and shape remain unchanged. Near-infrared and SWIR chemical imaging research has demonstrated the ability to map API and excipient distribution, evaluate blend homogeneity, characterize tablet coatings, differentiate formulations and perform non-destructive pharmaceutical identity checks.

The production challenge is converting this spectral capability into a repeatable machine. Tablet curvature, capsule-shell variation, powder packing, coating thickness and packaging films all influence the optical measurement. The inspection model must therefore be developed with the same finished dosage forms, production lots and packaging structures that the machine will encounter. Identity verification, material differentiation, spatial uniformity mapping and quantitative API measurement should also be treated as separate levels of difficulty rather than combined into one broad promise.

The Kyptec Automation® SWIR Camera Lens collection provides pharmaceutical OEMs with a particularly useful foundation because its five focal lengths allow optical geometry to be selected around the inspection task while retaining a common 900–1700 nm platform. Wider geometries can support multiple-tablet or capsule inspection, the Kyptec Automation® KL-1412 25 MM SWIR Camera Lens can concentrate more of the sensor on controlled dosage-form inspection, and the Kyptec Automation® KL-1414 35 MM SWIR Camera Lens can support tighter pharmaceutical material-analysis geometries. The consistent F1.4, 2 MP, 2/3-inch and C-Mount architecture makes the family especially practical for machine builders developing several inspection variants.

For pharmaceutical buyers and OEMs, the most reliable design principle is therefore to define exactly what material difference must be detected before choosing the SWIR lens and classifier. Establish whether the target is wrong product identity, API heterogeneity, powder segregation, capsule-content variation, coating non-uniformity or packaging-material mismatch; determine the smallest spatial region that changes the quality decision; and then design wavelength selection, focal length, FOV, exposure and validation around that requirement. When those elements are engineered together, Kyptec Automation® SWIR Camera Lenses can provide a strong optical basis for non-destructive pharmaceutical inspection that goes substantially beyond ordinary visual quality control.